site stats

Gemini therapeutics press release

WebAug 10, 2024 · Gemini Therapeutics is a clinical-stage precision medicine company previously focused on developing novel therapeutic compounds to treat genetically … WebOct 5, 2024 · Gemini will concentrate its resources to advance GEM103 for the treatment of genetically defined age-related macular degeneration (AMD). GEM103 has the potential …

Gemini Therapeutics and Disc Medicine Announce Merger …

WebAug 10, 2024 · Gemini Therapeutics, Inc. Brian Piekos Gemini Therapeutics, Inc. (617) 401-4400 [email protected] Disc Medicine, Inc. Peg Rusconi (Media) Verge … WebAug 12, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Gemini Therapeutics (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today reported its financial results for the second quarter ended June 30, 2024 and provided a business … hearing aid cup https://tfcconstruction.net

8-K - SEC

WebOct 5, 2024 · Gemini will concentrate its resources to advance GEM103 for the treatment of genetically defined age-related macular degeneration (AMD). GEM103 has the potential to be a best-in-class complement regulator for the treatment of GA,” said Jason Meyenburg, Chief Executive Officer of Gemini Therapeutics, Inc. WebNov 13, 2024 · CAMBRIDGE, Mass. & SAN FRANCISCO--(BUSINESS WIRE)-- Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that the Phase 1 study of GEM103, the Company’s investigational treatment … WebNov 12, 2024 · Gemini Therapeutics, Inc. today announced that Raj Maturi, M.D., will present a poster at the 2024 Annual Meeting of the American Academy of … mountaineer vision center morgantown wv

Gemini Therapeutics and Disc Medicine Announce Merger …

Category:News Releases Apellis Pharmaceuticals, Inc.

Tags:Gemini therapeutics press release

Gemini therapeutics press release

Disc Medicine: New Therapies for Rare Blood Disorders

WebJun 22, 2024 · Gemini Therapeutics Announces Initial Data From Its Ongoing Phase 2a Study of GEM103 in Patients With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. ... press releases ... WebNov 23, 2024 · Find the latest press releases from Gemini Therapeutics, Inc. Common Stock (GMTX) at Nasdaq.com.

Gemini therapeutics press release

Did you know?

WebSep 1, 2024 · Gemini Therapeutics, Inc. (Nasdaq - GMTX) Under the terms of the agreement, Gemini will merge with Disc Medicine, Inc. (“Disc”). Pre-merger Gemini shareholders are expected to own ... WebAug 19, 2024 · The efficacy of Auvelity for major depressive disorder was demonstrated in the GEMINI placebo-controlled study and confirmatory evidence was established in the ASCEND study comparing Auvelity to …

WebApr 11, 2024 · Source: Gemini Therapeutics. Gemini Therapeutics announced that the phase 1 study of GEM103, the company’s investigational treatment for dry AMD, met all its endpoints. Results demonstrate that in 12 patients receiving a single intravitreal (IVT) injection of GEM103, there were no dose-limiting toxicities or treatment-related adverse … WebApr 6, 2024 · Gemini Therapeutics announced the completion of its business combination with FS Development Corp., a special purpose acquisition company (SPAC) spons. ... to restore regulation of the complement system in the eye and throughout the body,” Mr. Meyenburg said in a company news release. “I want to thank all those involved in …

WebJan 10, 2024 · IRON January 10, 2024. Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of GEM103’s … WebCompleted reverse merger with Gemini Therapeutics, debuting on Nasdaq as “IRON” and ending 2024 with approximately $194.6 million in cash and cash… read more Disc Medicine Announces Collaboration with National Institutes of Health for Phase 2 Clinical Study of Bitopertin in Patients with Diamond-Blackfan Anemia (DBA)

WebDec 27, 2024 · GEMINI THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware : 001-39438 : 85-1612845 (State or other jurisdiction of incorporation) ... Disc issued a press release announcing that the US Food and Drug Administration granted Orphan Drug Designation to bitopertin for the treatment of erythropoietic protoporphyria.

WebAug 10, 2024 · Gemini Therapeutics, Inc. and Disc Medicine, Inc. announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. ... Certain statements in this press release and the information incorporated herein by reference may constitute “forward-looking statements” for … hearing aid custom ear moldWebDec 29, 2024 · Disc Medicine Announces Completion of Merger with Gemini Therapeutics Disc Medicine Inc December 29, 2024, 5:15 PM · 7 min read The combined company will … mountaineer wallbangWebOn January 10, 2024, the Company issued a press release entitled “Gemini Therapeutics Provides GEM103 Program Update.” The information in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities … mountaineer vision center westover wv